Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Blocking the enzyme 11β-HSD1 might help treat obesity and metabolic issues.

This review discusses three classes of thiazole-bearing compounds in drug development and presents preclinical findings but reports no new experimental results, highlighting the need for further drug discovery.

This study discusses the potential of targeting 11β-HSD1 for treating metabolic syndrome and highlights emerging promising data from human trials on selective 11β-HSD1 inhibitors.

This review discusses the potential of targeting glucocorticoid action as a treatment strategy for obesity and type-2 diabetes, highlighting promising animal study results but reports no new clinical findings.

This review explores the potential of selective 11β-HSD1 inhibitors to improve insulin sensitivity in type 2 diabetes, emphasizing the need for more clinical research and reports no new clinical results.

This study found that certain pyrazole derivatives may serve as effective 5α-reductase inhibitors with potential use in the treatment of androgenetic alopecia, based on molecular docking analyses.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

This study reports that 2-(1-Adamantyl)-4H-thiochromen-4-on-6-O-sulfamate is the most potent steroid sulfatase inhibitor identified so far, exhibiting 170-fold higher activity than the lead compound estrone sulfamate.

This study reported that subcutaneous trastuzumab improved certain symptoms and did not negatively impact health-related quality of life in patients with early or metastatic HER2-overexpressing breast cancer.

Treatment with oral terbinafine and topical enilconazole was successful in resolving a Trichophyton dermatophytosis outbreak in L'Hoest's monkeys, with complete mycological cure achieved after eight weeks.

This study found that povidone iodine, thiabendazole ointment, captan ointment, and Burroughs Wellcome Ringworm Ointment were effective against Trichophyton equinum var. autotrophicum in horses, but large-scale use may be limited by practicality and cost.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

This study found that azelaic acid entrapped in transethosomes exhibited enhanced antidermatophyte activity and improved treatment outcomes in guinea pig models of dermatophytosis compared to free azelaic acid.

This study found that a single dose of TRP significantly reduced the number of UV-B-induced actinic keratosis lesions in a mouse model and was associated with improved skin histology and minimal side effects.

This study found that a novel thiohydantoin derivative, 3a, effectively inhibited androgen receptor activity in LNCaP cells and showed promising in vivo results by reducing testosterone-induced prostate changes, outperforming finasteride in mitigating prostate index and histopathological alterations.

In this study, dermatophytosis was prevalent among 52% of dogs and 70% of cats with skin lesions, with younger animals facing higher infection risks; combined itraconazole, clotrimazole, supportive care, and vaccination led to the fastest recovery.

In this study, itraconazole was reported to effectively alleviate clinical symptoms in patients with recalcitrant Trichophyton rubrum infections, though toenail infections often recurred, indicating the need for further research on long-term efficacy and safety.

In this study, amitraz was found to be an effective and well-tolerated treatment for resolving sarcoptic mange in alpacas, demonstrating no relapse over a 10-month follow-up.

This study found that olorofim demonstrated potent in vitro and in vivo antifungal activity against dermatophytes, resolving skin lesions in a guinea pig model similar to clotrimazole, suggesting it may be a promising treatment for dermatophytosis.

In a mouse hair-growth model, this study found that the optimized compound 39 matched the efficacy of pyrilutamide for androgenic alopecia, with faster response and maintained safety, suggesting it as a promising topical AR antagonist with reduced systemic toxicity risk.

In a hair-growth mouse model, this study reported that the novel AR antagonist candidate 39, derived from structural optimization of 14-P1, achieved similar efficacy to pyrilutamide with faster response and maintained safety, demonstrating potent AR antagonism and favorable pharmacokinetics with lower systemic toxicity risk.

This case study describes successful treatment of a siamang's persistent Microsporum canis infection using a sustained-release clotrimazole varnish, leading to lesion resolution after two years of clinical signs.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.

In this study, a dual soft drug design strategy improved the AR antagonist candidate 39, showing potent AR antagonism and good safety in a mouse hair-growth model, with similar efficacy to pyrilutamide but faster response.

Tavaborole is a safe and effective toenail fungus treatment, with the 5% solution being the best option.